Myelodysplastic Syndrome Awareness Campaign
Grupo Biotoscana promotes campaign to raise awareness of myelodysplastic syndrome.
Montevideo, Uruguay, October 23, 2018. To honor the Myelodysplastic Syndrome World Awareness Day, celebrated on October 25th, GBT Grupo Biotoscana launched a campaign to raise awareness and educate on the disease throughout the month.
Myelodysplastic syndrome, also called myelodysplasia or MDS, is a group of blood disorders characterized by the inability of bone marrow stem cells to grow into mature, functional blood cells1-5. The main symptoms of MDS are anemia, recurrent infections and bleeding. Given those are common symptoms, the dissemination of the signs and symptoms of MDS is important because in most cases they can be confused with other diseases, and it is common for patients to wait years for a correct diagnosis3,4. Age is the main risk factor for Myelodysplastic Syndrome because it facilitates the mutation in the DNA that causes the disease in the bone marrow. About 80% of patients with MDS are over 60 years of age and it is a frequent disease in patients over 70 years, affecting 30 in 100,0003. In Brazil, there are 7,600 new cases every year2.
Early diagnosis is important because it significantly increases the quality of life of the patient, reducing the chances of recurrent blood transfusion and in more severe cases, as in 30% of the time, the evolution of the disease to leukemia1. Clinical evaluation and the blood count are some of the tests that raise suspicion about MDS. To reach the diagnosis, myelogram and bone marrow biopsy may still be necessary, among other tests.
The only cure for MDS available is transplantation, however many patients are not eligible because of age and other medical conditions. GBT offers the best treatment alternative for myelodysplastic syndrome that helps the patient‘s bone marrow improve its function.
The campaign can be followed by the Facebook page /issoecoisadevelho.
1 Fenaux and Ades, Blood 2013;121:4280-86
2 Statistics Review, 1975-2011. National Cancer Institute. http://seer.cancer.gov/csr/1975_2011. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001- 2004, using data from the NAACCR and SEER programs. Blood 2008; 112:45-52.
3 Shammo JM, Foran JM, Houk A, et al. An examination of educational gaps in the diagnosis and treatment of myelodysplastic syndromes. Cancer Control. 2011; 18:65-7
4 Khan AM. Why are myelodysplastic syndromes unrecognized and underdiagnosed? A primary care perspective. Am J Med. 2012 Jul;125(7 Suppl): S15-7
5 Sekeres M. Myelodysplastic syndromes: it is all in the genes. J Clin Oncol. 2012; 30:1-3. 3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer